Navigation Links
Antiplatelets: 1 person, 1 dose?
Date:4/14/2011

Montreal, April 14, 2011 An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, for patients with high on-treatment platelet reactivity does not reduce the incidence on death, heart attacks and stent thrombosis after percutaneous coronary intervention (PCI). The results of the GRAVITAS trial conducted to determine whether high-dose clopidogrel is superior to standard-dose therapy for the prevention of cardiovascular events after percutaneous coronary intervention in patients with high on-treatment reactivity, have been published recently in the Journal of the American Medical Association.

The GRAVITAS (Gauging Responsiveness with A VerifyNow assay Impact on Thrombosis And Safety) study showed no benefit of double-dose compared with standard-dose clopidogrel and the results refute the strategy of uniformly doubling the dose of clopidogrel over six months for patients with high on-treatment platelet reactivity after PCI with drug-eluting stent. In the multicenter, randomized, double-blind, active-control trial, the use of high-dose compared with standard-dose clopidogrel did not reduce the incidence of adverse cardiac events such as death, nonfatal myocardial infarction or stent thrombosis.

"The results of GRAVITAS are surprising because they do not support a uniform treatment strategy of high-dose clopidogrel in patients with high on-treatment reactivity." said Dr. Jean-Franois Tanguay, interventional cardiologist at the Montreal Heart Institute, professor of medicine at the Universit de Montral and lead investigator in Canada. "Personalized medicine merits further investigation. We need to assess alternative treatment strategies incorporating platelet function testing as opposed to prescribe a fixed, higher dose."

Between July 2008 and April 2010, 2214 patients from 83 sites in North America had high on-treatment reactivity after being screened with platelet function testing 12 to 24 hours after PCI. They were randomly assigned to either higher (double-dose) or standard-dose clopidogrel for six months after drug-eluting stent implantation. An additional 586 patients without high on-treatment reactivity were selected at random and assigned to treatment with standard-dose clopidogrel. Clopidogrel exposure prior to enrollment was similar across all 3 treatment groups.

At six months, the rate of death from cardiovascular causes, nonfatal myocardial infarction or stent thrombosis was not different with high-dose (25 of 1109 patients) compared with standard-dose (25 of 1105 patients) clopidogrel in patients with high on-treatment reactivity. ''These low event rates reflect the excellent results we can obtain with drug-eluting stents'' said Dr. Tanguay.


'/>"/>

Contact: Julie Chevrette
julie.chevrette@icm-mhi.org
514-376-3330 x2641
Montreal Heart Institute
Source:Eurekalert

Related medicine news :

1. Drug addicts get hooked via prescriptions, keep using to feel like a better person, research shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: